Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 40 entries
Sorted by: Best Match Show Resources per page
Evaluation of liver transplant recipients.

Journal of clinical and experimental hepatology

Thuluvath PJ.
PMID: 25755386
J Clin Exp Hepatol. 2011 Dec;1(3):199-203. doi: 10.1016/S0973-6883(11)60238-7. Epub 2012 Jan 02.

The outcome of liver transplantation (LT) is dependent on many factors including graft quality, surgical techniques, postoperative care, immunosuppressive regimens and most importantly, careful pre-transplant recipient evaluation and selection. Currently, the expected 1-year and 5-year survival rates after LT...

Cite
Thuluvath PJ. Evaluation of liver transplant recipients. J Clin Exp Hepatol. 2012;1(3):199-203doi: 10.1016/S0973-6883(11)60238-7.
Thuluvath, P. J. (2011). Evaluation of liver transplant recipients. Journal of clinical and experimental hepatology, 1(3), 199-203. https://doi.org/10.1016/S0973-6883(11)60238-7
Thuluvath, Paul J. "Evaluation of liver transplant recipients." Journal of clinical and experimental hepatology vol. 1,3 (2011): 199-203. doi: https://doi.org/10.1016/S0973-6883(11)60238-7
Thuluvath PJ. Evaluation of liver transplant recipients. J Clin Exp Hepatol. 2011 Dec;1(3):199-203. doi: 10.1016/S0973-6883(11)60238-7. Epub 2012 Jan 02. PMID: 25755386; PMCID: PMC3940623.
Copy Download .nbib Format: NLM
Utility and Safety of EUS-guided Portal Vein FNA.

Gastroenterology & hepatology

Kantsevoy S, Thuluvath PJ.
PMID: 21475422
Gastroenterol Hepatol (N Y). 2011 Feb;7(2):129-31.

No abstract available.

Cite
Kantsevoy S, Thuluvath PJ. Utility and Safety of EUS-guided Portal Vein FNA. Gastroenterol Hepatol (N Y). 2011;7(2):129-31
Kantsevoy, S., & Thuluvath, P. J. (2011). Utility and Safety of EUS-guided Portal Vein FNA. Gastroenterology & hepatology, 7(2), 129-31.
Kantsevoy, Sergey, and Thuluvath, Paul J. "Utility and Safety of EUS-guided Portal Vein FNA." Gastroenterology & hepatology vol. 7,2 (2011): 129-31.
Kantsevoy S, Thuluvath PJ. Utility and Safety of EUS-guided Portal Vein FNA. Gastroenterol Hepatol (N Y). 2011 Feb;7(2):129-31. PMID: 21475422; PMCID: PMC3061019.
Copy Download .nbib Format: NLM
NEWSworthy but Not Ready for Prime Time.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Thuluvath PJ.
PMID: 29596985
Clin Gastroenterol Hepatol. 2018 Oct;16(10):1566-1568. doi: 10.1016/j.cgh.2018.03.023. Epub 2018 Mar 27.

No abstract available.

Cite
Thuluvath PJ. NEWSworthy but Not Ready for Prime Time. Clin Gastroenterol Hepatol. 2018;16(10):1566-1568doi: 10.1016/j.cgh.2018.03.023.
Thuluvath, P. J. (2018). NEWSworthy but Not Ready for Prime Time. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 16(10), 1566-1568. https://doi.org/10.1016/j.cgh.2018.03.023
Thuluvath, Paul J. "NEWSworthy but Not Ready for Prime Time." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. 16,10 (2018): 1566-1568. doi: https://doi.org/10.1016/j.cgh.2018.03.023
Thuluvath PJ. NEWSworthy but Not Ready for Prime Time. Clin Gastroenterol Hepatol. 2018 Oct;16(10):1566-1568. doi: 10.1016/j.cgh.2018.03.023. Epub 2018 Mar 27. PMID: 29596985.
Copy Download .nbib Format: NLM
Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology.

Journal of clinical and experimental hepatology

Doycheva I, Zhang T, Amjad W, Thuluvath PJ.
PMID: 32655232
J Clin Exp Hepatol. 2020 Jul-Aug;10(4):296-303. doi: 10.1016/j.jceh.2019.11.004. Epub 2019 Nov 22.

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) remains the leading cause of cancer-related death among patients with type 2 diabetes mellitus (T2DM). We aimed to assess the independent role of T2DM on HCC risk among patients with different liver disease etiologies.METHODS: We...

Cite
Doycheva I, Zhang T, Amjad W, et al. Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology. J Clin Exp Hepatol. 2019;10(4):296-303doi: 10.1016/j.jceh.2019.11.004.
Doycheva, I., Zhang, T., Amjad, W., & Thuluvath, P. J. (2020). Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology. Journal of clinical and experimental hepatology, 10(4), 296-303. https://doi.org/10.1016/j.jceh.2019.11.004
Doycheva, Iliana, et al. "Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology." Journal of clinical and experimental hepatology vol. 10,4 (2020): 296-303. doi: https://doi.org/10.1016/j.jceh.2019.11.004
Doycheva I, Zhang T, Amjad W, Thuluvath PJ. Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology. J Clin Exp Hepatol. 2020 Jul-Aug;10(4):296-303. doi: 10.1016/j.jceh.2019.11.004. Epub 2019 Nov 22. PMID: 32655232; PMCID: PMC7335702.
Copy Download .nbib Format: NLM
Rectal reconstruction after endoscopic submucosal dissection for removal of a giant rectal lesion.

VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy

Kantsevoy SV, Wagner A, Mitrakov AA, Thuluvath AJ, Berr F.
PMID: 31032467
VideoGIE. 2019 Jan 31;4(4):179-181. doi: 10.1016/j.vgie.2018.12.001. eCollection 2019 Apr.

No abstract available.

Cite
Kantsevoy SV, Wagner A, Mitrakov AA, et al. Rectal reconstruction after endoscopic submucosal dissection for removal of a giant rectal lesion. VideoGIE. 2019;4(4):179-181doi: 10.1016/j.vgie.2018.12.001.
Kantsevoy, S. V., Wagner, A., Mitrakov, A. A., Thuluvath, A. J., & Berr, F. (2019). Rectal reconstruction after endoscopic submucosal dissection for removal of a giant rectal lesion. VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy, 4(4), 179-181. https://doi.org/10.1016/j.vgie.2018.12.001
Kantsevoy, Sergey V, et al. "Rectal reconstruction after endoscopic submucosal dissection for removal of a giant rectal lesion." VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy vol. 4,4 (2019): 179-181. doi: https://doi.org/10.1016/j.vgie.2018.12.001
Kantsevoy SV, Wagner A, Mitrakov AA, Thuluvath AJ, Berr F. Rectal reconstruction after endoscopic submucosal dissection for removal of a giant rectal lesion. VideoGIE. 2019 Jan 31;4(4):179-181. doi: 10.1016/j.vgie.2018.12.001. eCollection 2019 Apr. PMID: 31032467; PMCID: PMC6477183.
Copy Download .nbib Format: NLM
Vaccination in Chronic Liver Disease: An Update.

Journal of clinical and experimental hepatology

Alukal JJ, Naqvi HA, Thuluvath PJ.
PMID: 34975241
J Clin Exp Hepatol. 2021 Dec 08; doi: 10.1016/j.jceh.2021.12.003. Epub 2021 Dec 08.

Patients with chronic liver disease (CLD) with or without cirrhosis remain at risk of developing hepatic decompensation when infected with viral or bacterial pathogens. The Advisory Committee on Immunization Practices (ACIP) currently recommends vaccination in CLD against hepatitis A...

Cite
Alukal JJ, Naqvi HA, Thuluvath PJ. Vaccination in Chronic Liver Disease: An Update. J Clin Exp Hepatol. 2021;doi: 10.1016/j.jceh.2021.12.003.
Alukal, J. J., Naqvi, H. A., & Thuluvath, P. J. (2021). Vaccination in Chronic Liver Disease: An Update. Journal of clinical and experimental hepatology, . https://doi.org/10.1016/j.jceh.2021.12.003
Alukal, Joseph J, et al. "Vaccination in Chronic Liver Disease: An Update." Journal of clinical and experimental hepatology vol. (2021). doi: https://doi.org/10.1016/j.jceh.2021.12.003
Alukal JJ, Naqvi HA, Thuluvath PJ. Vaccination in Chronic Liver Disease: An Update. J Clin Exp Hepatol. 2021 Dec 08; doi: 10.1016/j.jceh.2021.12.003. Epub 2021 Dec 08. PMID: 34975241; PMCID: PMC8710401.
Copy Download .nbib Format: NLM
If Hoofbeats are not From Horses, It Could be Zebras!! Isolated Hyper-alkaline Phosphatasemia.

Journal of clinical and experimental hepatology

Chauhan M, Alpers DH, Hamilton JP, Thuluvath PJ.
PMID: 34511824
J Clin Exp Hepatol. 2021 Sep-Oct;11(5):619-622. doi: 10.1016/j.jceh.2020.12.001. Epub 2020 Dec 17.

Alkaline phosphatase (AP) is a membrane bound enzyme and when it is elevated in blood, it is mostly due to either hepatobiliary or bone diseases. We report isolated intestinal hyperphosphatasemia (IAP) in two sisters. Both sisters presented with identical...

Cite
Chauhan M, Alpers DH, Hamilton JP, et al. If Hoofbeats are not From Horses, It Could be Zebras!! Isolated Hyper-alkaline Phosphatasemia. J Clin Exp Hepatol. 2020;11(5):619-622doi: 10.1016/j.jceh.2020.12.001.
Chauhan, M., Alpers, D. H., Hamilton, J. P., & Thuluvath, P. J. (2021). If Hoofbeats are not From Horses, It Could be Zebras!! Isolated Hyper-alkaline Phosphatasemia. Journal of clinical and experimental hepatology, 11(5), 619-622. https://doi.org/10.1016/j.jceh.2020.12.001
Chauhan, Mahak, et al. "If Hoofbeats are not From Horses, It Could be Zebras!! Isolated Hyper-alkaline Phosphatasemia." Journal of clinical and experimental hepatology vol. 11,5 (2021): 619-622. doi: https://doi.org/10.1016/j.jceh.2020.12.001
Chauhan M, Alpers DH, Hamilton JP, Thuluvath PJ. If Hoofbeats are not From Horses, It Could be Zebras!! Isolated Hyper-alkaline Phosphatasemia. J Clin Exp Hepatol. 2021 Sep-Oct;11(5):619-622. doi: 10.1016/j.jceh.2020.12.001. Epub 2020 Dec 17. PMID: 34511824; PMCID: PMC8414313.
Copy Download .nbib Format: NLM
Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab.

Journal of clinical and experimental hepatology

Amjad W, Kotiah S, Gupta A, Morris M, Liu L, Thuluvath PJ.
PMID: 32189935
J Clin Exp Hepatol. 2020 Mar-Apr;10(2):185-187. doi: 10.1016/j.jceh.2019.11.009. Epub 2019 Dec 05.

The use of immunotherapy in transplant recipients is considered a contraindication because of very high risks for graft loss. The graft loss is to be expected because cytotoxic T-lymphocyte-associated protein-4 and programmed death 1 pathways are implicated in graft...

Cite
Amjad W, Kotiah S, Gupta A, et al. Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab. J Clin Exp Hepatol. 2019;10(2):185-187doi: 10.1016/j.jceh.2019.11.009.
Amjad, W., Kotiah, S., Gupta, A., Morris, M., Liu, L., & Thuluvath, P. J. (2020). Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab. Journal of clinical and experimental hepatology, 10(2), 185-187. https://doi.org/10.1016/j.jceh.2019.11.009
Amjad, Waseem, et al. "Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab." Journal of clinical and experimental hepatology vol. 10,2 (2020): 185-187. doi: https://doi.org/10.1016/j.jceh.2019.11.009
Amjad W, Kotiah S, Gupta A, Morris M, Liu L, Thuluvath PJ. Successful Treatment of Disseminated Hepatocellular Carcinoma After Liver Transplantation With Nivolumab. J Clin Exp Hepatol. 2020 Mar-Apr;10(2):185-187. doi: 10.1016/j.jceh.2019.11.009. Epub 2019 Dec 05. PMID: 32189935; PMCID: PMC7067990.
Copy Download .nbib Format: NLM
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.

Journal of hepatology

Frenette C, Kayali Z, Mena E, Mantry PS, Lucas KJ, Neff G, Rodriguez M, Thuluvath PJ, Weinberg E, Bhandari BR, Robinson J, Wedick N, Chan JL, Hagerty DT, Kowdley KV.
PMID: 33038432
J Hepatol. 2021 Feb;74(2):274-282. doi: 10.1016/j.jhep.2020.09.029. Epub 2020 Oct 08.

BACKGROUND & AIMS: Non-alcoholic steatohepatitis is a leading cause of end-stage liver disease. Hepatic steatosis and lipotoxicity cause chronic necroinflammation and direct hepatocellular injury resulting in cirrhosis, end-stage liver disease and hepatocellular carcinoma. Emricasan is a pan-caspase inhibitor that...

Cite
Frenette C, Kayali Z, Mena E, et al. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. J Hepatol. 2020;74(2):274-282doi: 10.1016/j.jhep.2020.09.029.
Frenette, C., Kayali, Z., Mena, E., Mantry, P. S., Lucas, K. J., Neff, G., Rodriguez, M., Thuluvath, P. J., Weinberg, E., Bhandari, B. R., Robinson, J., Wedick, N., Chan, J. L., Hagerty, D. T., Kowdley, K. V. (2021). Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. Journal of hepatology, 74(2), 274-282. https://doi.org/10.1016/j.jhep.2020.09.029
Frenette, Catherine, et al. "Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis." Journal of hepatology vol. 74,2 (2021): 274-282. doi: https://doi.org/10.1016/j.jhep.2020.09.029
Frenette C, Kayali Z, Mena E, Mantry PS, Lucas KJ, Neff G, Rodriguez M, Thuluvath PJ, Weinberg E, Bhandari BR, Robinson J, Wedick N, Chan JL, Hagerty DT, Kowdley KV. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. J Hepatol. 2021 Feb;74(2):274-282. doi: 10.1016/j.jhep.2020.09.029. Epub 2020 Oct 08. PMID: 33038432.
Copy Download .nbib Format: NLM
Acute-on-chronic liver failure in liver transplant candidates with non-alcoholic steatohepatitis.

Translational gastroenterology and hepatology

Doycheva I, Thuluvath PJ.
PMID: 32632389
Transl Gastroenterol Hepatol. 2020 Jul 05;5:38. doi: 10.21037/tgh.2019.10.01. eCollection 2020.

Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease worldwide. It is expected that non-alcoholic steatohepatitis (NASH), NASH-related cirrhosis and its decompensated forms will increase further in the next two decades. Acute-on-chronic liver failure (ACLF) is...

Cite
Doycheva I, Thuluvath PJ. Acute-on-chronic liver failure in liver transplant candidates with non-alcoholic steatohepatitis. Transl Gastroenterol Hepatol. 2020;5:38doi: 10.21037/tgh.2019.10.01.
Doycheva, I., & Thuluvath, P. J. (2020). Acute-on-chronic liver failure in liver transplant candidates with non-alcoholic steatohepatitis. Translational gastroenterology and hepatology, 538. https://doi.org/10.21037/tgh.2019.10.01
Doycheva, Iliana, and Thuluvath, Paul J. "Acute-on-chronic liver failure in liver transplant candidates with non-alcoholic steatohepatitis." Translational gastroenterology and hepatology vol. 5 (2020): 38. doi: https://doi.org/10.21037/tgh.2019.10.01
Doycheva I, Thuluvath PJ. Acute-on-chronic liver failure in liver transplant candidates with non-alcoholic steatohepatitis. Transl Gastroenterol Hepatol. 2020 Jul 05;5:38. doi: 10.21037/tgh.2019.10.01. eCollection 2020. PMID: 32632389; PMCID: PMC7063516.
Copy Download .nbib Format: NLM
Esophageal capsule endoscopy is not the optimal technique to determine the need for primary prophylaxis in patients with cirrhosis.

Archives of medical science : AMS

Krok KL, Wagennar RR, Kantsevoy SV, Thuluvath PJ.
PMID: 27186182
Arch Med Sci. 2016 Apr 01;12(2):365-71. doi: 10.5114/aoms.2016.59263. Epub 2016 Apr 12.

INTRODUCTION: Capsule endoscopy has been suggested as a potential alternative to endoscopy for detection of esophagogastric varices and severe portal hypertensive gastropathy (PHG). The aim of the study was to determine whether PillCam esophageal capsule endoscopy could replace endoscopy...

Cite
Krok KL, Wagennar RR, Kantsevoy SV, et al. Esophageal capsule endoscopy is not the optimal technique to determine the need for primary prophylaxis in patients with cirrhosis. Arch Med Sci. 2016;12(2):365-71doi: 10.5114/aoms.2016.59263.
Krok, K. L., Wagennar, R. R., Kantsevoy, S. V., & Thuluvath, P. J. (2016). Esophageal capsule endoscopy is not the optimal technique to determine the need for primary prophylaxis in patients with cirrhosis. Archives of medical science : AMS, 12(2), 365-71. https://doi.org/10.5114/aoms.2016.59263
Krok, Karen L, et al. "Esophageal capsule endoscopy is not the optimal technique to determine the need for primary prophylaxis in patients with cirrhosis." Archives of medical science : AMS vol. 12,2 (2016): 365-71. doi: https://doi.org/10.5114/aoms.2016.59263
Krok KL, Wagennar RR, Kantsevoy SV, Thuluvath PJ. Esophageal capsule endoscopy is not the optimal technique to determine the need for primary prophylaxis in patients with cirrhosis. Arch Med Sci. 2016 Apr 01;12(2):365-71. doi: 10.5114/aoms.2016.59263. Epub 2016 Apr 12. PMID: 27186182; PMCID: PMC4848367.
Copy Download .nbib Format: NLM
A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma.

Annals of translational medicine

Ravindran N, Thuluvath PJ.
PMID: 33178785
Ann Transl Med. 2020 Oct;8(19):1253. doi: 10.21037/atm-2020-71.

No abstract available.

Cite
Ravindran N, Thuluvath PJ. A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma. Ann Transl Med. 2020;8(19):1253doi: 10.21037/atm-2020-71.
Ravindran, N., & Thuluvath, P. J. (2020). A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma. Annals of translational medicine, 8(19), 1253. https://doi.org/10.21037/atm-2020-71
Ravindran, Nishal, and Thuluvath, Paul J. "A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma." Annals of translational medicine vol. 8,19 (2020): 1253. doi: https://doi.org/10.21037/atm-2020-71
Ravindran N, Thuluvath PJ. A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma. Ann Transl Med. 2020 Oct;8(19):1253. doi: 10.21037/atm-2020-71. PMID: 33178785; PMCID: PMC7607078.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 40 entries